Table 1 Correlations between PHLDA3 expression and clinicopathological factors in lung cancers.
n | PHLDA3-negative | PHLDA3-positive | p value | |
|---|---|---|---|---|
Tissues | <0.001 | |||
Normal | 108 | 108(100.0%) | 0(0.0%) | |
Lung cancer | 206 | 146(70.9%) | 60(29.1%) | |
Age | 0.160 | |||
<60 | 101 | 67(66.3%) | 34(33.7%) | |
≥60 | 105 | 79(75.2%) | 26(24.8%) | |
Sex | 0.008 | |||
Male | 144 | 110(76.4%) | 34(23.6%) | |
Female | 62 | 36(58.1%) | 26(41.9%) | |
Histological type | 0.009 | |||
Squamous cell carcinoma | 98 | 78(79.6%) | 20(20.4%) | |
Adenocarcinoma | 108 | 68(63.0%) | 40(37.0%) | |
Differentiation | 0.333 | |||
Well | 20 | 17(85.0%) | 3(15.0%) | |
Moderate | 136 | 95(69.9%) | 41(30.1%) | |
Poor | 50 | 34(68.0%) | 16(32.0%) | |
TNM stages | 0.006 | |||
I | 32 | 29(90.6%) | 3(9.4%) | |
II | 133 | 94(70.7%) | 39(29.3%) | |
III–IV | 41 | 23(56.1%) | 18(43.9%) | |
Lymphatic metastasis | 0.049 | |||
Yes | 105 | 68(64.8%) | 37(35.2%) | |
No | 101 | 78(77.2%) | 23(22.8%) | |
Tumor status | 0.005 | |||
T1 | 42 | 38(90.5%) | 4(9.5%) | |
T2 | 132 | 89(67.4%) | 43(32.6%) | |
T3–T4 | 32 | 19(59.4%) | 13(40.6%) |
